MoST Core Studies (C1) | Omico

Industry
Researchers
Clinicians
Patients & Families
Advocacy Groups
Our Programs
- - - PROGRAMS
    - PrOSPeCT
    - PrOSPeCT is our landmark precision oncology initiative and the largest cancer genomics initiative in Australia
    - Cancer Screening Program (CaSP)
    - Bringing comprehensive genomic profiling to patients with advanced and incurable cancer
    - Molecular Screening and Therapeutics (MoST) study
    - Using the power of genomic technology to characterise molecular changes in a patient's cancer
    - Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+)
    - Investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer
    - Genetic Cancer Risk in the Young (RisC) study – Now closed
    - Understanding the genetic variants that contribute to inherited cancer
  - - CLINICAL TRIALS
    - Company Studies (C3)
    - Companion Studies (C2)
    - MoST Core Studies (C1)
    - MoST-LLy
    - ASPiRATION
Resources & Events
About Us
News
Contact

Resources & Events
About Us
News
Contact

Sign up for newsletter

Refer a patient

Home

MoST therapeutic studies

Company Studies (C3)

Companion Studies (C2)

MoST Core Studies (C1)

MoST Core Studies (C1)

These are the substudies developed under the MoST Framework protocol.

Our Network

A national network of sites recruiting patients into our programs

Interested in knowing more?

Get in touch

Privacy Policy
Omico is registered not-for-profit company
Site Map
Sign Up for Newsletter